Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VRCA
Verrica Pharmaceuticals Inc. (VRCA) P/E ratio
Verrica Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XBIT XBiotech Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)